Caprylic Acid
Best-in-class: Caprylic Acid
A medium-chain fatty acid used in antifungal and candida protocols. Honest read: the in-vitro data is real and the human evidence is essentially absent.
Caprylic Acid quick facts
| Suggested dose | As directed; often taken as part of a combination protocol. |
| How often | Daily during a course, usually in combination |
| Who it's for | Antifungal protocols, in full knowledge of the evidence level. |
Used for Candida overgrowth, and the absorption issue means enteric or sustained-release formulations reach the target far better than plain caprylic acid. Human evidence is thin; most of the case is in vitro plus clinical experience. Intestinal fungal overgrowth is genuinely over-diagnosed relative to how often it is confirmed.
How Caprylic Acid actually works
A medium-chain fatty acid that disrupts fungal cell membranes, dissolving into the lipid bilayer and causing leakage. The selectivity for fungi over bacteria comes from differences in membrane composition. It is also rapidly absorbed, which is the practical problem — much of it is taken up before reaching the colon.
Where to get Caprylic Acid
Find Caprylic Acid on iHerb →What it is, why it recurs, and where this fits — free to read.
The evidence for Caprylic Acid
Graded by what exists behind each claim.
✅ Clinically validated
- No good human trials for candida overgrowth or gut dysbiosis.
📊 Correlative data
- Occurs naturally in coconut oil, palm kernel oil and human breast milk. The antimicrobial interest originated from observing that breast milk lipids have antimicrobial activity, which is an observation about the food rather than about the isolated fatty acid.
🧪 Theoretical / extrapolated benefits
- Demonstrated in-vitro antifungal activity against Candida species, likely through membrane disruption. Whether meaningful concentrations reach the colon after absorption in the small intestine is the unanswered question — and it's a big one.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Caprylic Acid actually does
Caprylic acid is octanoic acid: an eight-carbon saturated fatty acid with one carboxyl group and a pKa around 4.9. Everything interesting about it, for and against, follows from that pKa, and no page in this category does the arithmetic.
The antifungal mechanism requires the uncharged molecule. A short fatty acid kills a yeast by partitioning into the membrane and carrying protons across it — the uncharged acid dissolves in the bilayer, crosses, releases its proton into the more alkaline cytosol and acidifies it, and the charged anion left behind cannot get back out. Membrane fluidity rises, the transmembrane pH gradient collapses and the cell stops. Only the protonated form can do the first step.
So compute where the protonated form exists. With a pKa of 4.9, the Henderson-Hasselbalch ratio at colonic pH 7.0 is about 126 ionized to 1 un-ionized — roughly 0.8% of the molecule is in the form that can enter a membrane. In the stomach at pH 2 it is essentially all in the active form. The active species therefore exists exactly where absorption is fastest and the organism is not the problem, and has almost vanished by the time you reach the compartment the product is sold for. That single calculation is the honest core of this page.
The named genetic effect is real and it is not killing. Caprylic acid down-regulated ECE1 in Candida albicans by 5208-fold Jadhav 2017. ECE1 encodes the precursor of candidalysin, the peptide toxin that hyphal C. albicans uses to damage epithelium, and switching it off is a virulence effect rather than a cidal one. That is a more interesting and more plausible mechanism than sterilizing a colon, and it is also a mechanism that needs the molecule present at the mucosa in its active form.
The eight-carbon molecule is not the star of its own literature. When fatty acids and monoglycerides were tested head-to-head against C. albicans, capric acid — the ten-carbon homolog — produced the fastest and most effective killing Bergsson 2001. The animal work in oral candidiasis was also done with capric acid, not caprylic Takahashi 2012. A product named after C8 is standing on data that mostly belongs to C10.
Cell, rodent, human — and where it stops
The dish. Three strains of C. albicans were exposed to a panel of fatty acids and monoglycerides, and killing was rapid, with capric acid the most effective of them Bergsson 2001. Separately, capric and caprylic acid were shown to suppress virulence factors — adhesion, hyphal transition, biofilm — with the 5208-fold ECE1 suppression as the headline Jadhav 2017. Both are cell-free or cell-culture experiments with the compound applied directly to the organism at a known concentration.
The rodent, and read the route. In a murine oral candidiasis model, 50 µL of capric acid at above 48.8 µM was applied three times to the oral cavity and tongue symptom scores improved significantly Takahashi 2012. That is topical application to a visible mucosal surface in a mouse, using the other homolog. It is not a swallowed capsule, it is not the colon, and it is not C8.
The human step does not exist for the marketed use. There is no controlled human trial of oral caprylic acid for intestinal Candida, for dysbiosis or for any gut symptom. What does exist is decades of clinical nutrition work on medium-chain triglycerides as an energy source in malabsorption, hyperlipidemia, epilepsy and obesity Bach 1982 — a literature about feeding people, not about killing yeast.
The obstacle is pharmacokinetic, and it is the one this product cannot argue its way past. Medium-chain fatty acids are absorbed in the proximal small intestine. The received story is that they go straight into the portal vein rather than into lymph — and when somebody actually cannulated both and measured, the twelve-carbon acid went 51 ± 6% into lymph and under 1% into the portal vein Sigalet 1997. So even the chain-length boundary is not where the marketing puts it. What both routes share is that they empty the lumen. Whichever vessel it leaves by, it has left.
State the size of the gap plainly. To act on a colonic organism, an eight-carbon acid would have to survive gastric emptying, escape absorption across six meters of small intestine, and then arrive in a compartment where 99% of it is deprotonated and cannot cross a membrane. Three obstacles, none measured in a person, and the product is sold as though none of them existed.
Caprylic Acid — which form, and does it matter
A “caprylic acid” capsule is usually a salt, and that changes the first thing that happens to it. Free octanoic acid is a corrosive, foul-smelling liquid, so capsules are typically calcium or magnesium caprylate, a solid salt that becomes free acid on contact with gastric acid. That is a release step, and it happens in the stomach — the compartment where the molecule is both fully active and fully absorbable.
C8 MCT oil is a different molecule again. The oil sold as “C8” is tricaprylin, a triglyceride, and it releases caprylic acid only after pancreatic and gastric lipases cut it. That is an intestinal event with its own timing, and it means the ketogenic supplement and the antifungal supplement are chemically different products with the same marketing word on the front Bach 1982.
The delayed-release claim is the only formulation argument that is even trying. If the mechanism needs the acid past the ileum, then an uncoated salt is the wrong vehicle by design. Nobody has published a release profile, a colonic concentration or a comparison between coated and uncoated for this compound — so a “delayed release” caprylate is an untested idea rather than a solved problem.
And if you were buying the evidence rather than the name, you would buy capric. C10 was the most effective in the comparison Bergsson 2001 and it is the homolog the animal work used Takahashi 2012. Coconut-derived MCT preparations contain both, in a ratio the label usually gives, which makes the C8/C10 split one of the few genuinely informative numbers on these bottles.
What would have to be true, and how you would know it was not
1. Count episodes, not sensations, and say so before you start. The only scoreable endpoint here is confirmed thrush episodes per quarter, written down before the first capsule. There is no human trial for the marketed use, so what you are running is an uncontrolled n-of-1 against an in-vitro result Bergsson 2001 Jadhav 2017, and it deserves to be labeled that way rather than dressed up as a protocol.
2. The prediction that cuts against the product. Predict a null result at four weeks, and predict that a null result will be uninformative about the molecule. If 99% of the dose is ionized by the time it reaches the colon and most of it was absorbed before that, then failure is a delivery failure and tells you nothing about whether octanoic acid can kill yeast. That is an unusual and important thing to know in advance: this experiment cannot exonerate the compound.
3. Run the blood test that could actually explain recurrent thrush. Predict that in a meaningful minority of people with genuinely recurrent candidiasis, hba1c and fasting glucose on a cmp come back raised — because unrecognized hyperglycemia is a documented driver of mucosal candidiasis and is treatable. That prediction is cheap, it is checkable in one draw, and it beats any capsule in this category.
4. Expect ketones and a loose bowel, and do not read either as antifungal action. Medium-chain fats are rapidly oxidized and ketogenic Bach 1982, and they loosen stool at gram doses. Predict both at doses of a few grams a day, predict neither carries any information about yeast, and predict cbc stays exactly where it was. The reaction people call “die-off” in the first week is indistinguishable from the gastrointestinal effect of swallowing a detergent-like fatty acid, and no test has ever separated them.
What nobody has tested yet
Nobody has measured caprylic acid in a human colon. One intubation or capsule-sampling study, reporting octanoate concentration and luminal pH in the distal ileum and right colon after a defined oral dose, would settle the entire question this page is built on. It has never been published, which is remarkable for a compound sold for colonic use for forty years.
Nobody has compared C8 with C10 in a person. The comparison exists in vitro and it favors capric acid Bergsson 2001; the animal work is capric Takahashi 2012; the product is caprylic. A three-arm human trial with a fungal culture endpoint would take one season and has never been funded.
Nobody has tested the virulence hypothesis where it would matter. Suppressing ECE1 by three orders of magnitude Jadhav 2017 predicts less candidalysin and less epithelial damage without necessarily reducing fungal counts — which means the right endpoint is mucosal damage, not a culture. No trial has used that endpoint, and it is the one where this compound could plausibly win.
And nobody has established that the target condition exists in the people being treated. There is no validated definition of intestinal Candida overgrowth in an immunocompetent adult and no agreed threshold on a stool culture. Until somebody defines the disease, no trial of any antifungal for it can be designed, which is the deepest reason this evidence base is empty.
Caprylic Acid — its own safety story, not its category's
It is corrosive as a free acid, which is why the delivery form matters for safety and not just for efficacy. Octanoic acid at concentration irritates mucosa. Nausea, heartburn and burning are the common complaints, they are the chemistry rather than an idiosyncratic reaction, and they are the reason the material is sold as a calcium or magnesium salt in the first place.
The “die-off” framing is the specific safety hazard of this product. A protocol that reinterprets worsening symptoms as evidence of success is a protocol with no stopping rule. Medium-chain fats loosen stool and cause cramping by a mechanism that has nothing to do with yeast Bach 1982, so the sensation that is being read as proof is fully explained by the vehicle. If symptoms escalate, the correct inference is dose, not victory.
It is metabolic, and that is where a real interaction lives. Medium-chain fatty acids are rapidly oxidized and ketogenic Bach 1982. On a ketogenic diet, on an SGLT2 inhibitor, or during prolonged fasting, adding several grams a day of a ketogenic substrate is stacking with things that already raise ketones. That is a quantitative interaction nobody in this category mentions because nobody thinks of a candida capsule as a fat.
The honest limit is that there is no human trial to be reassured by. Everything above is chemistry and animal work Bergsson 2001 Takahashi 2012 Jadhav 2017. The absence of reported harm from a compound that has never been studied at supplement doses in people is not a safety record. It is an absence of study, and the two are constantly confused on pages like this one.
Sources read for this page
- Bergsson G. In vitro killing of Candida albicans by fatty acids and monoglycerides. Antimicrob Agents Chemother 2001 · PMID 11600381
- Jadhav A, Mortale S, Halbandge S, et al. The Dietary Food Components Capric Acid and Caprylic Acid Inhibit Virulence Factors in Candida albicans Through Multitargeting. Journal of Medicinal Food 2017 · PMID 28922057
- Takahashi M. [Inhibition of Candida mycelia growth by a medium chain fatty acids, capric acid in vitro and its therapeutic efficacy in murine oral candidiasis]. Med Mycol J 2012 · PMID 23257726
- Bach AC. Medium-chain triglycerides: an update. Am J Clin Nutr 1982 · PMID 6814231
- Sigalet DL. Determination of the route of medium-chain and long-chain fatty acid absorption by direct measurement in the rat. JPEN J Parenter Enteral Nutr 1997 · PMID 9323689
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: Thrush episodes per quarter, counted, because that is the only endpoint in this protocol specific enough to score. There are no good human trials for gut candida with this compound, so what you are running is an n-of-1 against an in-vitro finding and it should be labeled that way from the start.
- How long before it means anything: Four weeks is a fair test, but the mechanism has a delivery problem worth knowing first: C8 is absorbed high in the small intestine, so whether meaningful amounts ever reach the colon is unresolved. A null result here may be a delivery failure rather than an inactive molecule.
- What will fool you: It almost always arrives inside a combination protocol with three or four other antifungals, which makes attribution impossible. MCT oil and coconut oil are common in the same crowd too, so the exposure may have started long before the capsules did.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Caprylic Acid — safety & side effects
- GI upset, nausea and heartburn are common.
- A 'die-off' reaction reported when starting usually means the dose is too high.
- Long-term safety has not been characterized — the trials run weeks to months, not years. That is a real limit on what anyone can tell you about daily use for a decade. No established significant drug interactions.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Caprylic Acid in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Caprylic Acid
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Complete Blood Count (CBC) with Differential | Anemia is the commonest sign of a gut absorbing badly |
| Ferritin | Iron is the first thing malabsorption takes |
| Vitamin B12 | The second thing, and the one with permanent consequences |
| hs-CRP (High-Sensitivity C-Reactive Protein) | Separates inflammatory bowel disease from IBS |
The Gut Health & Absorption panel covers these in one order — 11 markers, $208.80 with the discount applied.
Check results you already have → · All 103 markers A–Z
Caprylic Acid — frequently asked questions
What is Caprylic Acid?
A medium-chain fatty acid used in antifungal and candida protocols. Honest read: the in-vitro data is real and the human evidence is essentially absent.
What is the suggested dose of Caprylic Acid?
As directed; often taken as part of a combination protocol. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Caprylic Acid dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Caprylic Acid?
Coach Cam sources Caprylic Acid from vetted, top-rated brands on iHerb — use the buy link on this page.
What Caprylic Acid is used for
Caprylic Acid appears under 1 goal in the goal router.
Related Gut & Digestion supplements
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.